<DOC>
	<DOCNO>NCT01090063</DOCNO>
	<brief_summary>The purpose study determine short long term safety effectiveness ustekinumab subject moderate severe chronic palmar plantar psoriasis .</brief_summary>
	<brief_title>Efficacy Safety Ustekinumab Patients With Moderate Severe Palmar Plantar Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>1 . Adults 18 85 year age palmar plantar psoriasis well define psoriatic plaque palm and/or sol Physician Global Assessment ( PGA ) 3 high unresponsive topical management . Pustules , fissure psoriatic arthritis may present require . 2 . Adults general good health determine Investigator base upon result medical history , laboratory profile , physical examination . 3 . Females reproductive potential eligible participate study negative urine pregnancy test screen baseline use 2 form effective birth control . 4 . Palmar/Plantar PGA 3 1 . Psoriasis patient without palm and/or sole psoriasis palmar/plantar PGA score less 3 2 . Patients young 18 old 85 year old . 3 . Evidence skin condition time screen visit ( e.g . eczema ) psoriasis would interfere evaluation effect study medication psoriasis 4 . Receipt investigational drug within 4 week study drug initiation 5 . Psoralens + UltraViolet A ( PUVA ) oral systemic treatment within 4 week study drug initiation . 6 . Biologics within 3 month study initiation 7 . Ultraviolet B ( UVB ) therapy topical steroid within 2 week study drug initiation 8 . A prior history tuberculosis , and/or positive Purified Protein Derivative ( PPD ) skin test/Chest XRay ( CXR ) screen without appropriate treatment . Treatment latent Tuberculosis ( TB ) infection ( positive PPD test ) must initiate prior therapy . 9 . Receipt live vaccine 1 month prior study 10 . Chronic hepatitis B hepatitis C infection 11 . History alcohol drug abuse one year study . 12 . Known Human Immunodeficiency Virus ( HIV ) positive status immunesuppressing disease . 13 . Any grade 3 4 adverse event , laboratory toxicity , time screen visit time study 14 . Presence grade 3 4 infection &lt; 30 day prior screen visit , screen visit first day treatment study , time study opinion Investigator would preclude participation study . 15 . Any internal malignancy within 5 year ( fully excise cutaneous , basal cell carcinoma squamous cell carcinoma exception )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Palmar Plantar Psoriasis</keyword>
</DOC>